Glucose oxidase stabilised in Oxyzyme™ - a commercial wound dressing
Insense Ltd is a speciality woundcare company that developed the Oxyzyme™ wound care dressing. This was the first application of Arecor's stabilisation technology.
This revolutionary dressing generates oxygen through a two-layered hydrogel in which glucose oxidase protein enzyme reacts with atmospheric oxygen using a glucose substrate to produce a continuous release of reactive oxygen. This kills infections and facilitates the healing of chronic wounds.
The problem to be solved: the enzyme activity of glucose oxidase in the wound dressing was lost after gamma radiation sterilisation (25kG). The enzyme activity also needed to be stable after storage at room temperature for up to two years.
Strategy: Arestat-R™ technology was used to stabilise the glucose oxidase in the wound dressing.
Results:
-
the glucose oxidase in the wound dressing retained almost full activity immediately following irradiation and upon storage.
-
the product has been approved in Europe for a two-year shelf life; more than three years' shelf stability at 40°C has now been demonstrated.
Problem solved: glucose oxidase is now available in a market-ready hydrogel dressing stored at ambient temperature and following sterilisation by gamma irradiation.
Last updated: 13 June 2008